Cargando…

Role of Glucuronidation Pathway in Quetiapine Metabolism: An In vivo Drug–Drug Interaction Study between Quetiapine and Probenecid

BACKGROUND: Uridine 5'-diphospho-glucuronosyltransferase (UGT) enzymes play a significant role in the metabolism of quetiapine, and coadministration with a UGT inhibitor/inducer drug may change its pharmacokinetic profile. OBJECTIVE: The objective of this study was to assess the impact of probe...

Descripción completa

Detalles Bibliográficos
Autores principales: Sattar, Haseeb, Jadoon, Sarmad Sheraz, Yang, Ni, Li, Shihong, Xu, Mingzhen, Han, Yong, Ramzan, Adil, Li, Weiyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7485652/
https://www.ncbi.nlm.nih.gov/pubmed/32952511
http://dx.doi.org/10.4103/sjmms.sjmms_441_19
_version_ 1783581184846987264
author Sattar, Haseeb
Jadoon, Sarmad Sheraz
Yang, Ni
Li, Shihong
Xu, Mingzhen
Han, Yong
Ramzan, Adil
Li, Weiyong
author_facet Sattar, Haseeb
Jadoon, Sarmad Sheraz
Yang, Ni
Li, Shihong
Xu, Mingzhen
Han, Yong
Ramzan, Adil
Li, Weiyong
author_sort Sattar, Haseeb
collection PubMed
description BACKGROUND: Uridine 5'-diphospho-glucuronosyltransferase (UGT) enzymes play a significant role in the metabolism of quetiapine, and coadministration with a UGT inhibitor/inducer drug may change its pharmacokinetic profile. OBJECTIVE: The objective of this study was to assess the impact of probenecid, a UGT enzyme inhibitor, on the pharmacokinetic profile of quetiapine. MATERIALS AND METHODS: Twelve treatment-naïve, 7-week-old male Sprague–Dawley rats (weighting 161 ± 22 g) were randomly and equally divided into control, quetiapine-alone and quetiapine plus probenecid groups. The quetiapine plus probenecid group received a single oral dose of probenecid (50 mg/kg) followed by 50 mg/kg of quetiapine; the quetiapine-alone group only received 50 mg/kg of quetiapine. Blood samples (0.2 ml) were collected from all rats after 0, 0.25, 0.5, 1, 2, 4, 6, 8, 10, 12 and 24 h of the drug administration in heparinized tubes. The pre-established liquid chromatography–mass spectrometry method was utilized to ascertain the plasma concentration of quetiapine and the control group was used to prepare the controlled standard. RESULTS: Significant pharmacokinetic differences were observed between the quetiapine-alone and quetiapine plus probenecid groups in terms of C(max) (392 ± 209 vs. 1323 ± 343 ug/L, respectively, P = 0.004), AUC(0-∞) (P = 0.04) and T(max) (P = 0.004). Further, in the combined drug group, there was a decrease in drug clearance (CL/F) (from 27 ± 11 to 16 ± 3 L/h/kg; P = 0.005) and an increase in the volume of distribution (Vd) (P = 0.01), but there was no significant difference between both groups in terms of half-lives (P = 0.27). No significant within-group variability of pharmacokinetic parameters was observed (P = 0.25). CONCLUSION: The results of this animal study suggest that glucuronidation by UGT enzyme system may also play an important role in quetiapine metabolism, which, if proven in future human studies, would imply that the bioavailability and pharmacokinetic parameters of quetiapine may require alterations when co-administered with probenecid to avoid development of quetiapine toxicity.
format Online
Article
Text
id pubmed-7485652
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-74856522020-09-18 Role of Glucuronidation Pathway in Quetiapine Metabolism: An In vivo Drug–Drug Interaction Study between Quetiapine and Probenecid Sattar, Haseeb Jadoon, Sarmad Sheraz Yang, Ni Li, Shihong Xu, Mingzhen Han, Yong Ramzan, Adil Li, Weiyong Saudi J Med Med Sci Original Article BACKGROUND: Uridine 5'-diphospho-glucuronosyltransferase (UGT) enzymes play a significant role in the metabolism of quetiapine, and coadministration with a UGT inhibitor/inducer drug may change its pharmacokinetic profile. OBJECTIVE: The objective of this study was to assess the impact of probenecid, a UGT enzyme inhibitor, on the pharmacokinetic profile of quetiapine. MATERIALS AND METHODS: Twelve treatment-naïve, 7-week-old male Sprague–Dawley rats (weighting 161 ± 22 g) were randomly and equally divided into control, quetiapine-alone and quetiapine plus probenecid groups. The quetiapine plus probenecid group received a single oral dose of probenecid (50 mg/kg) followed by 50 mg/kg of quetiapine; the quetiapine-alone group only received 50 mg/kg of quetiapine. Blood samples (0.2 ml) were collected from all rats after 0, 0.25, 0.5, 1, 2, 4, 6, 8, 10, 12 and 24 h of the drug administration in heparinized tubes. The pre-established liquid chromatography–mass spectrometry method was utilized to ascertain the plasma concentration of quetiapine and the control group was used to prepare the controlled standard. RESULTS: Significant pharmacokinetic differences were observed between the quetiapine-alone and quetiapine plus probenecid groups in terms of C(max) (392 ± 209 vs. 1323 ± 343 ug/L, respectively, P = 0.004), AUC(0-∞) (P = 0.04) and T(max) (P = 0.004). Further, in the combined drug group, there was a decrease in drug clearance (CL/F) (from 27 ± 11 to 16 ± 3 L/h/kg; P = 0.005) and an increase in the volume of distribution (Vd) (P = 0.01), but there was no significant difference between both groups in terms of half-lives (P = 0.27). No significant within-group variability of pharmacokinetic parameters was observed (P = 0.25). CONCLUSION: The results of this animal study suggest that glucuronidation by UGT enzyme system may also play an important role in quetiapine metabolism, which, if proven in future human studies, would imply that the bioavailability and pharmacokinetic parameters of quetiapine may require alterations when co-administered with probenecid to avoid development of quetiapine toxicity. Wolters Kluwer - Medknow 2020 2020-08-20 /pmc/articles/PMC7485652/ /pubmed/32952511 http://dx.doi.org/10.4103/sjmms.sjmms_441_19 Text en Copyright: © 2020 Saudi Journal of Medicine & Medical Sciences http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Sattar, Haseeb
Jadoon, Sarmad Sheraz
Yang, Ni
Li, Shihong
Xu, Mingzhen
Han, Yong
Ramzan, Adil
Li, Weiyong
Role of Glucuronidation Pathway in Quetiapine Metabolism: An In vivo Drug–Drug Interaction Study between Quetiapine and Probenecid
title Role of Glucuronidation Pathway in Quetiapine Metabolism: An In vivo Drug–Drug Interaction Study between Quetiapine and Probenecid
title_full Role of Glucuronidation Pathway in Quetiapine Metabolism: An In vivo Drug–Drug Interaction Study between Quetiapine and Probenecid
title_fullStr Role of Glucuronidation Pathway in Quetiapine Metabolism: An In vivo Drug–Drug Interaction Study between Quetiapine and Probenecid
title_full_unstemmed Role of Glucuronidation Pathway in Quetiapine Metabolism: An In vivo Drug–Drug Interaction Study between Quetiapine and Probenecid
title_short Role of Glucuronidation Pathway in Quetiapine Metabolism: An In vivo Drug–Drug Interaction Study between Quetiapine and Probenecid
title_sort role of glucuronidation pathway in quetiapine metabolism: an in vivo drug–drug interaction study between quetiapine and probenecid
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7485652/
https://www.ncbi.nlm.nih.gov/pubmed/32952511
http://dx.doi.org/10.4103/sjmms.sjmms_441_19
work_keys_str_mv AT sattarhaseeb roleofglucuronidationpathwayinquetiapinemetabolismaninvivodrugdruginteractionstudybetweenquetiapineandprobenecid
AT jadoonsarmadsheraz roleofglucuronidationpathwayinquetiapinemetabolismaninvivodrugdruginteractionstudybetweenquetiapineandprobenecid
AT yangni roleofglucuronidationpathwayinquetiapinemetabolismaninvivodrugdruginteractionstudybetweenquetiapineandprobenecid
AT lishihong roleofglucuronidationpathwayinquetiapinemetabolismaninvivodrugdruginteractionstudybetweenquetiapineandprobenecid
AT xumingzhen roleofglucuronidationpathwayinquetiapinemetabolismaninvivodrugdruginteractionstudybetweenquetiapineandprobenecid
AT hanyong roleofglucuronidationpathwayinquetiapinemetabolismaninvivodrugdruginteractionstudybetweenquetiapineandprobenecid
AT ramzanadil roleofglucuronidationpathwayinquetiapinemetabolismaninvivodrugdruginteractionstudybetweenquetiapineandprobenecid
AT liweiyong roleofglucuronidationpathwayinquetiapinemetabolismaninvivodrugdruginteractionstudybetweenquetiapineandprobenecid